Reading Your Pathology Report

Your pathology report is a detailed map of your cancer. It is a document created by a pathologist—a doctor who studies tissues under a microscope—to describe the size, speed, and fuel sources of the tumor ^[1]. Because ER-positive breast cancer can behave in many different ways, understanding the specific details in this report is the first step in tailoring your treatment. Note that pathology alone does not establish your full clinical stage or detect distant disease.

The Essential Elements Checklist

A complete pathology report for ER-positive breast cancer should include several key pieces of information. If any of these are missing, you should ask your care team for the “synoptic report” (a standardized summary) ^[2]:

• Histologic Type: The “name” of the cancer (e.g., Invasive Ductal Carcinoma or Invasive Lobular Carcinoma).
• Tumor Size: The largest dimension of the invasive part of the tumor, measured in millimeters or centimeters ^[1].
• Histologic Grade: Often called the Nottingham Grade, this measures how much the cancer cells look like healthy cells on a scale of 1 to 3 ^[1].
• ER and PR Percentage: The exact percentage of cells that reacted to estrogen and progesterone ^[2].
• HER2 Status: A marker that tells if the cancer has too much of a specific growth-promoting protein ^[3]. (This guide focuses on HER2-negative disease).
• Lymph Node Status: Whether the cancer has spread to nearby nodes and the size of any deposits ^[4].
• Margins: Whether there is a “clear” area of healthy tissue around the tumor that was removed. The standard for a clear margin is generally “no ink on tumor” for invasive cancer treated with whole-breast radiation.

Understanding the Biomarkers: ER, PR, and HER2

These markers are the “keys” to your treatment. They are usually measured using a technique called Immunohistochemistry (IHC), which uses special dyes to highlight specific proteins ^[2].

The Estrogen Receptor (ER) ‘Low Positive’ Category

While “ER-positive” is often used as a broad term, the actual percentage matters.

• ER Positive (>10%): These tumors are usually very responsive to hormone therapy ^[2].
• ER Low Positive (1-10%): This is a unique group. Research shows that tumors with only 1% to 10% ER staining often behave more like ER-negative (triple-negative) breast cancer ^[5]. They may be more likely to respond to chemotherapy, but endocrine therapy is generally still considered and treatment integrates the whole clinical picture ^[6][7]. If your result is in this range, your doctor may treat it with a combination of approaches ^[8].

The Role of Progesterone (PR)

The Progesterone Receptor (PR) acts as a signal that the estrogen pathway is working properly. If a tumor is ER-positive but PR-negative (or low), it is often a sign of a more aggressive “Luminal B” biology ^[9]. Low PR is an important prognostic factor, but it should not by itself dictate that you need chemotherapy; it is interpreted alongside grade, tumor size, and genomic assays ^[9][10].

The Ki-67 Marker: Measuring ‘Speed’

Ki-67 is a protein found in cells that are actively dividing. It is reported as a percentage; for example, a Ki-67 of 30% means 30% of the cancer cells evaluated are in the process of multiplying ^[11].

However, Ki-67 is famously difficult to measure consistently. Results can change depending on whether the pathologist counts cells manually or uses a computer, which part of the tumor they look at, and how the tissue was preserved ^[12][13]. Because of this variability, experts recommend that Ki-67 should not be used as the only reason to decide on chemotherapy ^[14]. It is an “adjunct”—one piece of a larger puzzle—and if the result is in a “gray area” (like 15-25%), your doctor might order a genomic test (like Oncotype DX) for a more precise answer ^[15].

Technical Terms Defined

As you read your report, you may encounter these specific terms:

• Invasive vs. In Situ: Invasive means the cancer has the potential to spread beyond the original site. In situ (like DCIS) means the cancer cells are still “in place” inside the milk ducts and have not yet invaded the surrounding tissue ^[16].
• Lymphovascular Invasion (LVI): This means cancer cells were seen inside small blood vessels or lymphatic channels within the breast tissue. It is a risk factor rather than proof that cancer has spread, and not an automatic indication for more surgery or radiation ^[17].
• Nodes (Sentinel vs. Axillary): The sentinel node is the first “gatekeeper” node where cancer would likely spread. A negative sentinel node substantially lowers the likelihood of additional nodal disease but does not guarantee that all other nodes are clear. If tumor deposits are found, they are classified by size:
  • Isolated Tumor Cells (ITCs): Tiny clusters (<0.2 mm) ^[4].
  • Micrometastases: Small deposits (0.2 mm to 2 mm) ^[4].
  • Macrometastases: Larger deposits (>2 mm) ^[4].

Understanding these details empowers you to ask more specific questions about why a particular treatment—like a specific type of hormone pill or a recommendation for radiation—is being suggested for your unique tumor biology.